science
Kalshi to Allow Bets on Drug Trial Results and FDA Decisions
Kalshi will allow bets on selected clinical trial results and full FDA decisions, starting with Phase 3 studies from established companies. The FDA separately approved Merck's Lipfendra cholesterol pill based on studies showing up to 60% LDL reduction.
Jul 16, 12:38 PM·1m read2 sources
news.ycombinator.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Kalshi plans to launch prediction markets allowing bets on clinical trial outcomes and FDA regulatory approvals. The exchange is partnering with AppliedXL to select and monitor the markets. Initially, Kalshi will allow bets only on Phase 3 trial outcomes run by established drug companies and on full FDA approval decisions.
The U.S. Food and Drug Administration approved Merck’s Lipfendra pill for lowering cholesterol. Lipfendra is a once-daily pill intended to reduce LDL cholesterol beyond what statins alone achieve. Approval was based on studies showing up to 60% reduction in LDL cholesterol over six months in adults with or at risk for atherosclerotic cardiovascular disease.
Analysts project Lipfendra peak annual sales exceeding $5 billion.
Transparency
How sources framed this
These outlets didn't split into competing frames — coverage was uniform.
CorroborationLimited · 2 sources
